MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
AVITA Medical Net Debt 2011-2026 | RCEL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AVITA Medical
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.1 M | 18.6 M | -17.2 M | -53.9 M | -71.7 M | -20.3 M | -10.8 M | -2.91 M | -3.12 M | -190 K | -3.43 M | -9.69 M | -8.42 M | -13.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.1 M | -71.7 M | -12 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Insulet Corporation
PODD
|
468 M | $ 216.0 | -4.21 % | $ 15.2 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Profound Medical Corp.
PROF
|
-7.36 M | $ 5.82 | 13.01 % | $ 180 M |  Canada |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
Quanterix Corporation
QTRX
|
7.4 M | $ 3.96 | 3.66 % | $ 169 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.33 | -1.85 % | $ 21.5 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 101.78 | 0.8 % | $ 1.29 B | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Sintx Technologies
SINT
|
-898 K | $ 2.56 | -0.39 % | $ 7.1 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 37.08 | 1.42 % | $ 1.15 B | USA |
 |
Smith & Nephew plc
SNN
|
1.5 B | - | - | $ 23.8 B |  Britain |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Sensus Healthcare
SRTS
|
-21.6 M | $ 4.22 | 6.57 % | $ 68.9 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
-636 K | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 24.66 | -0.16 % | $ 208 M | USA |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | Canada |
 |
Tactile Systems Technology
TCMD
|
-75.4 M | $ 26.96 | 0.37 % | $ 617 M | USA |
 |
TELA Bio
TELA
|
-5.65 M | $ 0.69 | -9.35 % | $ 15.8 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Tandem Diabetes Care
TNDM
|
239 M | $ 24.26 | -1.02 % | $ 1.65 B | USA |
 |
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.67 | -3.52 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
-4.85 M | $ 2.32 | 7.41 % | $ 3.62 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
InspireMD
NSPR
|
-5.65 M | $ 1.77 | -1.12 % | $ 114 M | Israel |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 11.39 | -0.78 % | $ 1.54 B | USA |
 |
Penumbra
PEN
|
-152 M | $ 336.27 | 0.63 % | $ 13.1 B | USA |
 |
Myomo
MYO
|
-4.79 M | $ 0.7 | -0.1 % | $ 29.3 M | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.71 | -5.12 % | $ 138 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 16.23 | 2.01 % | $ 381 M | USA |
 |
Outset Medical
OM
|
63 M | $ 3.53 | - | $ 53.7 K | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 51.41 | -1.27 % | $ 1.51 B | USA |
 |
Varex Imaging Corporation
VREX
|
225 M | $ 10.69 | 0.66 % | $ 443 M | USA |